Table 4.

List of genes reported to be significantly associated with immune-associated endpoints after radiotherapy. Only studies with >100 samples were included.

Endpoint	Tumor type*	Genes associated with the endpoint	Genes with contradictory results	References
Dermatitis	BC	ABCA1, IL12RB2		(Isomura et al., 2008)
	HNC	GSK3B, MDM2, XRCC1		(Borchiellini et al., 2017; Chen et al., 2017; Yu et al., 2016)
Esophagitis	LC	BLM HSPB1, PRKCE, TGFB1, TNFSF7		(Guerra et al., 2012; Lopez Guerra et al., 2011; Pu et al., 2014; Zhao et al., 2016)
Fibrosis	BC	ATM (lung fibrosis), Class III MHC region, GSTA1, GSTP1, TXNRD2	TGFB1, XRCC1	(Barnett et al., 2010; Barnett et al., 2012; Edvardsen et al., 2013; Edvardsen et al., 2007; Giotopoulos et al., 2007; Grossberg et al., 2018; Quarmby et al., 2003; Seibold et al., 2015; Talbot et al., 2012; Terrazzino et al., 2012)
	HNC	ATM, ERCC5, HDM2, XRCC1	XRCC3	(Alsbeih et al., 2014; Borchiellini et al., 2017; Cheuk et al., 2014)
	Several cancers	ATM		(Zhang et al., 2016)
IL6 levels	PC	RNASEL		(Meyer et al., 2010)
Mucositis	HNC	APC, ATG10, ATG16L2, EDN1, NBN	XRCC1	(Chen et al., 2017; Ma et al., 2017; Pratesi et al., 2011; Venkatesh et al., 2014; Yang and Liu, 2019; Yu et al., 2016)
Pneumonitis	LC	AKT2, ATG16L2, BMP2, DDX58, ERCC1, GSTP1, HIPK2, IL4, IL8, LIN28B, MTHFR, MUS81, NEIL1, NFKBIA, PI3CA, RAD51, SP-D, TNF, TOPBP1, TP53	APEX, ATM, CBLB, HSPB1, IL1A, IL13, LIG4, MIF, NOS3, TGFB1, TNFRSF1B, VEGF, XRCC1	(Chen et al., 2013; Du et al., 2018a; Du et al., 2018b; Hildebrandt et al., 2010; Li et al., 2014; Li et al., 2016; Mak et al., 2012; Niu et al., 2012; Pang et al., 2013; Pu et al., 2014; Tang et al., 2016; Tang et al., 2019; Tang et al., 2020; Voets et al., 2012; Wang and Bi, 2010; Wen et al., 2018; Wen et al., 2014; Xiong et al., 2013; Xu et al., 2019; Yang et al., 2017; Yang et al., 2011; Yin et al., 2011a; Yin et al., 2011b; Yin et al., 2012a; Yin et al., 2012b; Yuan et al., 2009; Zhang et al., 2010; Zhao et al., 2016)

^*BC, breast cancer; HNC, head and neck cancer; LC, lung cancer; PC, prostate cancer.